Zentiva, a leading European manufacturer known for producing affordable and high-quality medicines, has announced the EU-wide launch of its first monoclonal antibody biosimilar following approval by the European Medicines Agency. This launch represents Zentiva’s entry into the biosimilar market and reinforces the company’s commitment to improving patient access to essential therapies across Europe.
Health Technology Insights: Ardent Health Announces $50 Million Share Repurchase Program Authorization
Steffen Saltofte, CEO of Zentiva, described the launch as a major milestone for the company. He emphasized that moving into the field of biologic medicines is a natural extension of Zentiva’s mission to make high-quality treatments more widely accessible and cost-effective. Saltofte added that this expansion not only enhances patient care but also positions Zentiva for long-term growth in one of the fastest-growing segments of the pharmaceutical industry.
The newly launched biosimilar is a monoclonal antibody indicated for the treatment of bone-related conditions. It has been authorized through the EMA’s centralized approval process and will be gradually introduced across European markets beginning in December.
Health Technology Insights: PCI Pal Launches Secure Payment Solution for Healthcare Sector
Zentiva’s foray into biosimilars aligns with its broader strategic plan to diversify beyond traditional generics. As biologic therapies continue to represent a rising share of healthcare spending in Europe, the company believes that biosimilars are crucial for maintaining healthcare system sustainability and expanding patient access to modern, effective treatments.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 18 November 2025
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
